Bank Julius Baer & Co
IMDX

Bank Julius Baer & Co’s Insight Molecular Diagnostics IMDX Stock Holding History

Bank Julius Baer & Co’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-13,500
Closed -$375K – 834
2020
Q3 		$375K Buy
13,500
+6,000
+80% +$172K ﹤0.01% 423
2020
Q2 		$286K Buy
+7,500
New +$387K ﹤0.01% 422

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bank Julius Baer & Co's IMDX Position: Q4 2020 in Review

Bank Julius Baer & Co sold out of Insight Molecular Diagnostics (IMDX) in Q4 2020, closing a stake of 13,500 shares — an estimated $375K sold.

Bank Julius Baer & Co first reported a position in IMDX in Q2 2020 and held it in 2 quarters. The position peaked at $375K in Q3 2020. 60 funds tracked by Wall St. Rank hold IMDX as of Q4 2020.

  • Bank Julius Baer & Co reported no remaining Insight Molecular Diagnostics position as of Q4 2020 after selling out during the quarter.
  • Bank Julius Baer & Co sold 13,500 Insight Molecular Diagnostics shares in Q4 2020, an estimated $375K.
  • Bank Julius Baer & Co first reported a position in Insight Molecular Diagnostics in Q2 2020 and held it in 2 quarters.
  • Bank Julius Baer & Co's Insight Molecular Diagnostics position peaked at $375K in Q3 2020.
  • 60 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q4 2020.

Based on Bank Julius Baer & Co's 13F filing for Q4 2020, filed 12 Feb 2021.